126 related articles for article (PubMed ID: 31608715)
1. Economic evaluations of oral medications for breast cancer treatment in the U.S.: a systematic review with a focus on cost-effectiveness threshold.
Park SK; Chun HK; Park C
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):633-643. PubMed ID: 31608715
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.
Smieliauskas F; Chien CR; Shen C; Geynisman DM; Shih YC
Pharmacoeconomics; 2014 Jul; 32(7):651-80. PubMed ID: 24821281
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.
Yu A; Huang E; Abe M; An K; Park SK; Park C
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):381-393. PubMed ID: 33554675
[No Abstract] [Full Text] [Related]
4. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Diaby V; Tawk R; Sanogo V; Xiao H; Montero AJ
Breast Cancer Res Treat; 2015 May; 151(1):27-40. PubMed ID: 25893588
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analyses of drug therapies in breast cancer: a systematic review.
Nerich V; Saing S; Gamper EM; Kemmler G; Daval F; Pivot X; Holzner B
Breast Cancer Res Treat; 2016 Oct; 159(3):407-24. PubMed ID: 27572551
[TBL] [Abstract][Full Text] [Related]
6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers.
Lin C; Clark R; Tu P; Bosworth HB; Zullig LL
Breast Cancer Res Treat; 2017 Sep; 165(2):247-260. PubMed ID: 28573448
[TBL] [Abstract][Full Text] [Related]
9. Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries.
Vallejo-Torres L; García-Lorenzo B; Edney LC; Stadhouders N; Edoka I; Castilla-Rodríguez I; García-Pérez L; Linertová R; Valcárcel-Nazco C; Karnon J
Appl Health Econ Health Policy; 2022 May; 20(3):337-349. PubMed ID: 34964092
[TBL] [Abstract][Full Text] [Related]
10. A review of economic impact of targeted oral anticancer medications.
Shen C; Chien CR; Geynisman DM; Smieliauskas F; Shih YC
Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):45-69. PubMed ID: 24378038
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review.
Al-Ziftawi NH; Shafie AA; Mohamed Ibrahim MI
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):655-666. PubMed ID: 32657174
[TBL] [Abstract][Full Text] [Related]
12. An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.
Gogate A; Rotter JS; Trogdon JG; Meng K; Baggett CD; Reeder-Hayes KE; Wheeler SB
Breast Cancer Res Treat; 2019 Apr; 174(2):343-355. PubMed ID: 30603995
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
14. Adherence to targeted oral anticancer medications.
Geynisman DM; Wickersham KE
Discov Med; 2013 Apr; 15(83):231-41. PubMed ID: 23636140
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
Shiroiwa T; Fukuda T; Shimozuma K; Mouri M; Hagiwara Y; Kawahara T; Ohsumi S; Hozumi Y; Sagara Y; Ohashi Y; Mukai H
BMC Cancer; 2017 Nov; 17(1):773. PubMed ID: 29149882
[TBL] [Abstract][Full Text] [Related]
16. Global representativeness and impact of funding sources in cost-effectiveness research on systemic therapies for advanced breast cancer: A systematic review.
Lazar Neto F; de Melo MAZ; Hidalgo Filho CMT; Mathias-Machado MC; Testa L; Campolina AG
Breast; 2024 Jun; 75():103727. PubMed ID: 38603837
[TBL] [Abstract][Full Text] [Related]
17. Interpreting the economic literature in oncology.
Grusenmeyer PA; Wong YN
J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940
[TBL] [Abstract][Full Text] [Related]
18. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.
Norum J
Expert Opin Pharmacother; 2006 Aug; 7(12):1617-25. PubMed ID: 16872264
[TBL] [Abstract][Full Text] [Related]
20. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
